Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.

@article{Mehta2007EfficacyAS,
  title={Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.},
  author={Shamir R. Mehta and Christopher B. Granger and John W A Eikelboom and Jean-Pierre Bassand and Lars Wallentin and David P. Faxon and Ron J G Peters and Andrzej J. Budaj and Rizwan Afzal and Susan Chrolavicius and Keith A. A. Fox and Salim Yusuf},
  journal={Journal of the American College of Cardiology},
  year={2007},
  volume={50 18},
  pages={
          1742-51
        }
}
OBJECTIVES This study reports a prospectively planned analysis of patients with acute coronary syndrome who underwent early percutaneous coronary intervention (PCI) in the OASIS-5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. BACKGROUND In the OASIS-5 trial, fondaparinux was similar to enoxaparin for short-term efficacy, but reduced major bleeding by one-half and 30-day mortality by 17%. METHODS The OASIS-5 trial was a double-blind, randomized comparison of… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 100 CITATIONS

FILTER CITATIONS BY YEAR

2007
2018

CITATION STATISTICS

  • 5 Highly Influenced Citations

  • Averaged 2 Citations per year over the last 3 years

Similar Papers

Loading similar papers…